Wentz, Elisabet http://orcid.org/0000-0002-1264-6517
Dobrescu, Sandra Rydberg
Dinkler, Lisa
Gillberg, Carina
Gillberg, Christopher
Blennow, Kaj
Råstam, Maria
Zetterberg, Henrik
Funding for this research was provided by:
Jane och Dan Olssons Stiftelse (2015 and 2016-55))
Stiftelserna Wilhelm och Martina Lundgrens (vet2-73/2014, and 2017-1555))
Petter Silfverskiöld’s Memorial Foundation (2016-007)
Swedish State Support for Clinical Research (#ALFGBG-813401, #ALFGBG-715986)
Royal and Hvitfeldt’s Foundation (2016)
Queen Silvia Children’s Hospital Foundations (2018)
Queen Silvia’s Jubilee Fund (2016)
The Samariten foundation (2016-0150)
The Swedish Research Council (521-2012-1754, #2018-02532)
AnnMari and Per Ahlqvist Foundation, (2017)
Swedish State Support for Clinical Research (#ALFGBG 2018, #ALFGBG-720931)
The European Research Council (#681712)
The Swedish Research Council (#2017-00915)
Swedish Alzheimer Foundation (#AF-742881)
Hjärnfonden (#FO2017-0243)
The Birgit and Sten A. Olsson Foundation for research into mental disabilities (2011-2019)
University of Gothenburg
Article History
Received: 13 December 2019
Accepted: 2 October 2020
First Online: 11 October 2020
Compliance with ethical standards
:
: The following authors report financial relationships with commercial interests: Dr. Henrik Zetterberg has served at scientific advisory boards for Roche Diagnostics, Samumed, Wave and CogRx, has lectured in symposia sponsored by Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. Dr. Blennow has served as a consultant or at advisory boards for Abcam, Axon, Biogen, Lilly, MagQu, Novartis and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg.